ArticleInternational journal of oral science2026
ANKRD1 sustains a neurogenic BMSC niche and counters cognitive aging.
Article in International journal of oral science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toothache and Alzheimer's Disease: A Mendelian Randomization Study of the NAAG-CD33 Neuroimmune Axis.Journal of pain research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Craniomaxillofacial bone marrow mesenchymal stromal cells (BMSCs) retaining neural crest-derived neurogenic niche is driven by lineage memory and niche homeostasis. Elucidating how the neurogenic potential is maintained is critical for neurological health. Here, we explored a neural crest-like progenitor niche in BMSCs with high neurogenic and proliferative capacity by single-cell transcriptomics. In which, ANKRD1 is a pivotal regulator sustaining the neurogenic reservoir. Importantly, ANKRD1 expression in this niche declines with aging and lineage commitment, coinciding with its redistribution from a diffuse nucleoplasmic pattern to perinuclear enrichment along the nuclear lamina and loss of neural potential. Mechanistically, ANKRD1 preserves neurogenic capacity by directly binding super-enhancers of neural marker genes (SOX2, NESTIN) and maintaining open chromatin architecture. Critically, neuron-targeted ANKRD1 delivery rescues spatial memory deficits in aged mice. These findings establish ANKRD1 as a therapeutically tractable regulator that sustains neurogenic chromatin reservoirs to support neurocognitive resilience, opening avenues to counter cognitive aging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.